Cubist Pharmaceuticals (CBST) Given “Buy” Rating by Jefferies Group (JEF) Analysts

Cubist Pharmaceuticals (NASDAQ: CBST)‘s stock had its “buy” rating reiterated by Jefferies Group (NYSE: JEF) in a research note issued on Friday.Separately, analysts at Bank of America (NYSE: BAC) reiterated a “buy” rating on shares of Cubist Pharmaceuticals in a research note to investors on Friday.Cubist Pharmaceuticals, Inc. (Cubist) is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The Company’s products are used primarily in hospitals, but also may be used in acute care settings, including home infusion and hospital outpatient clinics. Cubist’s owns CUBICIN (daptomycin for injection), which is a once-daily, bactericidal, intravenous (I.V.) antibiotic with activity against certain Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (S. aureus), (MRSA). During the year ended December 31, 2009, this product was used in the treatment of more than an estimated 880,000 patients. In December 2009, the Company acquired Calixa Therapeutics Inc.Cubist Pharmaceuticals opened at 40.40 on Friday. Cubist Pharmaceuticals has a 52-week low of $21.17 and a 52-week high of $42.10. The stock has a 50-day moving average of $39.25 and a 200-day moving average of $36.18. The company has a market cap of $2.487 billion and a price-to-earnings ratio of 70.14.